Acute Lung Injury


Significant Decreases in Neutrophil Infiltration

In July 2020, ReAlta announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for RLS-0071 for the treatment of acute lung injury secondary to COVID-19. ReAlta expects to begin enrolling in the 2nd quarter of 2021 a Phase 1 randomized, double-blind, placebo-controlled clinical trial of RLS-0071 in adult patients with pneumonia and early respiratory failure.

In parallel, ReAlta is exploring the ability of RLS-0071 to treat acute lung injury triggered by other viral infections such as RSV and influenza, and in other acute pulmonary disease processes.

Normal Lung Histology Normal lung histology
Neutrophil Infiltration And Tissue Damage Neutrophil infiltration and tissue damage
Preserved lung histology after single dose of RLS-0071 Preserved lung histology after single dose of RLS-0071
Acute Lung Injury

Acute lung injury (ALI) associated with COVID-19 is the most frequent cause of death related to the infection, with limited benefit shown from current treatments.

Learn More
Hypoxic Ischemic Encephalopathy

Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.

Learn More
Hemolytic Transfusion Reactions

A hemolytic transfusion reaction is a serious complication that can occur after a blood transfusion.

Learn More
Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia is a group of disorders characterized by a malfunction of the immune system that produces autoantibodies, which attack red blood cells as if they were substances foreign to the body.

Learn More